Aquestive Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Aquestive Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $16.82M | Mar 14, 2019 |
| FY2018 | Sep 30, 2018 | $13.27M | Mar 14, 2019 |
| FY2018 | Jun 30, 2018 | $13.93M | Mar 14, 2019 |
| FY2018 | Mar 31, 2018 | $23.41M | Mar 14, 2019 |
| FY2018 | Dec 31, 2017 | $12.19M | Mar 14, 2019 |
| FY2018 | Sep 30, 2017 | $27.15M | Mar 14, 2019 |
| FY2018 | Jun 30, 2017 | $11.14M | Mar 14, 2019 |
| FY2018 | Mar 31, 2017 | $16.44M | Mar 14, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.55M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $57.56M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $50.58M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $47.68M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $50.83M | Mar 31, 2023 |
| FY2020 | Dec 31, 2020 | $7.15M | Mar 9, 2021 |
| FY2020 | Sep 30, 2020 | $8.26M | Mar 9, 2021 |
| FY2020 | Jun 30, 2020 | $21.68M | Mar 9, 2021 |
| FY2020 | Mar 31, 2020 | $8.77M | Mar 9, 2021 |
| FY2020 | Dec 31, 2019 | $16.42M | Mar 9, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($83.78M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($44.14M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($7.87M) | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | ($54.41M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($70.54M) | Mar 31, 2023 |
| FY2020 | Dec 31, 2020 | ($20.37M) | Mar 9, 2021 |
| FY2020 | Sep 30, 2020 | ($16.55M) | Mar 9, 2021 |
| FY2020 | Jun 30, 2020 | ($2.33M) | Mar 9, 2021 |
| FY2020 | Mar 31, 2020 | ($16.53M) | Mar 9, 2021 |
| FY2020 | Dec 31, 2019 | ($12.64M) | Mar 9, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($71.05M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($30.77M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($15.10M) | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | ($42.07M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($34.68M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($42.89M) | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | ($52.67M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($48.93M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($113.0K) | Mar 14, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.19M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $20.28M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $13.10M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $17.48M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $17.05M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $19.89M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $20.57M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $23.11M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $22.13M | Mar 14, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $79.85M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $50.18M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $31.75M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $52.88M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $53.48M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $55.89M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $64.34M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $72.27M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $25.08M | Mar 14, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($52.43M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($35.76M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($6.38M) | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | ($9.82M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($32.98M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($45.46M) | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | ($60.21M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($12.99M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $5.82M | Mar 14, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $562.0K | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $159.0K | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $995.0K | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $1.02M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $913.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $517.0K | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $663.0K | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $1.82M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $2.07M | Mar 14, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $160.43M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $101.42M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $57.42M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $57.07M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $61.99M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $62.88M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $78.48M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $86.85M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $43.12M | Mar 14, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $194.09M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $161.58M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $163.91M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $175.62M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $144.13M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $111.38M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $84.60M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $76.77M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $69.61M | Mar 14, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($33.66M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($60.16M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | ($106.49M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | ($118.55M) | Mar 5, 2025 |
| FY2023 | Dec 31, 2021 | ($82.13M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | ($48.50M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | ($6.12M) | Mar 8, 2022 |
| FY2020 | Dec 31, 2018 | $10.08M | Mar 9, 2021 |
| FY2019 | Dec 31, 2017 | ($26.50M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | ($57.20M) | Mar 14, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($447.00M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($363.21M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($319.08M) | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | ($311.21M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($256.80M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($186.26M) | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | ($130.47M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($61.38M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($120.09M) | Mar 14, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $31.81M | Mar 9, 2021 |
| FY2020 | Dec 31, 2019 | $49.33M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $60.60M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $17.38M | Mar 14, 2019 |
| FY2018 | Dec 31, 2016 | $9.21M | Mar 14, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.00M | Mar 4, 2026 |
| FY2024 | Dec 31, 2024 | $45.00M | Mar 5, 2025 |
| FY2023 | Dec 31, 2023 | $45.00M | Mar 5, 2024 |
| FY2020 | Dec 31, 2020 | $51.50M | Mar 9, 2021 |
| FY2019 | Dec 31, 2019 | $70.00M | Mar 11, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 8, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 8, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 122.04M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 91.41M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | 68.53M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | 54.83M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | 41.23M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 34.57M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | 33.56M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | 24.96M | Mar 11, 2020 |